- 首页
- PKC (Protein kinase C)
- VTX-27
VTX-27
A PKCθ inhibitor
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
2mg￥2437.001950.00- +
-
5mg￥4850.003880.00- +
-
10mg￥7775.006220.00- +
-
25mg￥15487.0012390.00- +
-
50mg￥25412.0020330.00- +
-
100mg￥36512.0029210.00- +
- 货号: ajce48066
- CAS: 1321924-70-2
- 别名:
- 分子式: C20H24ClFN6O
- 分子量: 418.9
- 纯度: ＞98%
- 溶解度: DMSO : 125 mg/mL (298.40 mM)
- 储存: Store at -20°C
- 库存: 现货
Background
VTX-27 is a PKCθ inhibitor (Ki = 0.08 nM).1 It is selective for PKCθ over PKCα, -βI, -βII, -γ, -δ, -ε, -η, -?, and -ζ with Ki values ranging from 1 to >5,000 nM as well as a panel of seven kinases from the Src, spleen tyrosine kinase (Syk), Tec, and MAP kinase families (Kis = >1,000 nM for all). VTX-27 inhibits CD28-induced IL-2 release in isolated human peripheral blood mononuclear cells (PBMCs; IC50 = 11 nM). Oral administration of VTX-27 (12.5, 25, and 50 mg/kg) prevents staphylococcal enterotoxin B-induced increases in IL-2 plasma levels in mice.
1.Jimenez, J.-M., Boyall, D., Brenchley, G., et al.Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseasesJ. Med. Chem.56(5)1799-1810(2013)
